Table 2.
Characterization of individuals above and below 264 BAU/mL in the two groups: vaccinated and naive to infection and vaccinated and previously infection
| Characteristics | Vaccinated and naive to infection (VNI) | Vaccinated and previously infected (VPI) | p-value1 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IgG Spike < 264 BAU/mL | IgG Spike > 264 BAU/mL | p-value1 | Total | IgG Spike < 264 BAU/mL | IgG Spike > 264 BAU/mL | p-value1 | Total | Total: VNI vs VPI | < 264 BAU/mL: VNI vs VPI | > 264 BAU/mL: VNI vs VPI | |
| n | 165 | 137 | 212 | 27 | 68 | 68 | |||||
| M/F | 31/134 | 22/115 | 0.76 | 40/172 | 4/23 | 18/30 | 0.038* | 17/51 | 0.3 | 0.65 | 0.0038** |
| Age (years), median (IQR) | 50 (42; 57) | 47 (39; 56) | 0.045* | 49 (41; 56) | 51 (37; 56) | 51 (39; 57) | 0.59 | 51 (39.3; 57) | 0.85 | 0.55 | 0.33 |
| BMI (ratio), median (IQR) | 23.6 (21.8; 26.9) | 23.7 (22; 26.4) | 0.59 | 23.6 (21.7; 26.9) | 23.4 (21.9; 25.2) | 25 (22.3; 28.6) | 0.09 | 24.2 (22.2; 26.6) | 0.5 | 0.54 | 0.19 |
| Comorbidities (n, %) | 82 (49.7%) | 50 (36.5%) | 0.027* | 90 (42.5%) | 15 (55.6%) | 30 (44.1%) | 0.37 | 32 (47.1%) | 0.57 | 0.68 | 0.36 |
| HCWs (n, %) | 41 (24.8%) | 38 (27.8%) | 0.6 | 51 (24.1%) | 11 (40.8%) | 21 (30.9%) | 0.48 | 21 (30.9%) | 0.27 | 0.1 | 0.74 |
| Time between infection and sampling (days), median (IQR) | – | – | – | 387 (109; 453) | 285 (235.5; 398.3) | 0.42 | 236 (80; 243) | – | – | – | |
| Time between vaccination and sampling (days), median (IQR) | 176 (134; 212.5) | 73 (32.5; 142.5) | < 0.0001 | 145 (66; 194) | 188 (127; 230) | 102 (47.3; 153.8) | 0.0021** | 112 (47; 196) | 0.28 | 0.65 | 0.049* |
| Number of vaccine doses, (n, %) | 2 (165, 100%) | 2 (137, 100%) | – | 2 (212, 100%) | 1 (14, 51.9%); 2 (13, 48.1%) | 1 (47, 69.1%); 2 (21, 30.9%) | 0.15 | 1 (43, 63.2%); 2 (25, 36.8%) | – | – | |
| Anti-SP IgG (BAU/mL), median (IQR) | 109 (63; 158.5) | 722 (465.5; 1331) | < 0.0001 | 208 (97; 630.5) | 138 (51; 185) | 914.5 (460.8; 1617) | < 0.0001 | 473 (185; 1396) | < 0.0001 | 0.3 | 0.19 |
| Neutralization of Wuhan variant, median (IQR) | 2.5 (1.5; 4.5) | 12.8 (8.2; 23.6) | < 0.0001 | 6.3 (2.4; 12.8) | 4.8 (2.1; 8.8) | 18.2 (11.7; 51.2) | < 0.0001 | 15 (6.6; 34.4) | < 0.0001 | 0.009** | 0.0013** |
| Neutralization of Alpha variant, median (IQR) | 2.1 (1.2; 3.5) | 11.1 (6.3; 20.6) | < 0.0001 | 4.8 (2; 10.5) | 4.2 (1.8; 9.4) | 17.2 (11.2; 47.8) | < 0.0001 | 13.5 (6.1; 34.3) | < 0.0001 | 0.0027** | < 0.0001 |
| Neutralization of Delta variant, median (IQR) | 2.3 (1.5; 4) | 11.6 (6.7; 21.2) | < 0.0001 | 5.1 (2.8; 10.8) | 4.4 (1.9; 8.5) | 19.6 (11.7; 51.8) | < 0.0001 | 13.8 (6.1; 41.4) | < 0.0001 | 0.01* | < 0.0001 |
| SARS-CoV-2 specific T cell response (IU/mL), median (IQR) | 0.21 (0.09; 0.42) | 0.29 (0.16; 0.9) | 0.0023** | 0.23 (0.1; 0.54) | 0.2 (0.095; 0.68) | 0.65 (0.31; 1.9) | 0.0014** | 0.52 (0.23; 1.23) | < 0.0001 | 0.72 | 0.0018** |
N number, IQR interquartile range, HCW health care workers, Anti-SP anti-Spike, IgG immunoglobulin G, Anti-N anti-nucleocapsid
*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005
1Mann-Whitney test for quantitative variables; Fisher’s exact test for qualitative variables. All tests are two-sided with statistical significance p < 0.05